ABOUT US

Phenex – Translating Science into Medicines

We identify novel therapeutic targets from literature and our own experiments. We validate them extensively in proprietary research programs. This provides the basis for the identification of novel small molecule-based drug candidates with “game changing” capabilities.

Phenex has a track record of identifying new mechanisms from the literature and has already translated two of them into novel therapeutic small molecules that moved into clinical development.

The first program, RORγt inverse agonists, was in inflammation and autoimmune diseases – which is partnered since late 2012 with Janssen Biotech in a deal valued at USD 135 M.

The second was the FXR program, geared towards a drug for Non-Alcoholic Steatohepatitis (NASH), Primary Biliary Cholangitis (PBC) and other severe liver diseases – this was acquired by Gilead Sciences in late 2014 in a USD 465 M deal.

Since, both companies – Janssen and Gilead – have progressed our development candidates into the clinic, Phenex can expect further milestone payments in the next few years.

The significant payments from these deals enabled Phenex not only to advance a next generation program for NASH but also to invest significantly into novel research programs at the crossroads of (immune)metabolism and cancer.

OUR R&D PROGRAMS

Overview R & D Programs Phenex R 6 D Programs Phenex

OUR INVESTORS

Phenex has raised about 20 Mio Euro in venture capital since its inception in 2002. The company is strongly supported by the following venture capital funds & family offices:

LXR / NASH

Cancer Metabolism

AHR / IDO Cancer

About Phenex